Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mendelics | RCV002249451 | SCV002518921 | benign | not specified | 2022-05-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002249451 | SCV003658260 | uncertain significance | not specified | 2024-09-02 | criteria provided, single submitter | clinical testing | The c.56G>A (p.G19D) alteration is located in exon 2 (coding exon 1) of the PLXNA3 gene. This alteration results from a G to A substitution at nucleotide position 56, causing the glycine (G) at amino acid position 19 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Institute of Human Genetics, |
RCV000736201 | SCV000864498 | likely pathogenic | Short stature | 2001-11-18 | no assertion criteria provided | case-control | |
Prevention |
RCV003392576 | SCV004120019 | uncertain significance | PLXNA3-related disorder | 2024-06-10 | no assertion criteria provided | clinical testing | The PLXNA3 c.56G>A variant is predicted to result in the amino acid substitution p.Gly19Asp. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.039% of alleles in individuals of European (Non-Finnish) descent in gnomAD, including 16 hemizygous individuals. Although we suspect this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |